Berman Capital Advisors’s Kyntra Bio KYNB Stock Holding History

Berman Capital Advisors’s Portfolio KYNB Stock Details KYNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	$0	Buy	3 +2	+200%	+$709	﹤0.01%	2117
2021 Q2	$0	Hold	1	–	–	﹤0.01%	1940
2021 Q1	$1K	Hold	1	–	–	﹤0.01%	1631
2020 Q4	$1K	Hold	1	–	–	﹤0.01%	1525
2020 Q3	$1K	Hold	1	–	–	﹤0.01%	1447
2020 Q2	$1K	Buy	+1	New	+$929	﹤0.01%	1417
2019 Q2	–	Sell	-5	Closed	-$6K	–	1498
2019 Q1	$6K	Buy	5 +2	+67%	+$2.71K	﹤0.01%	811
2018 Q4	$3K	Buy	+3	New	+$3.37K	﹤0.01%	797

Other funds holding KYNB

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Berman Capital Advisors's KYNB Position: Q3 2021 in Review

Berman Capital Advisors increased its Kyntra Bio (KYNB) stake by 200% in Q3 2021, buying an estimated $709 and bringing the position to 3 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #2117.

Berman Capital Advisors first reported a position in KYNB in Q4 2018 and has held it in 8 quarters since. The position peaked at $6K in Q1 2019. 164 funds tracked by Wall St. Rank hold KYNB as of Q3 2021.

Berman Capital Advisors held 3 shares of Kyntra Bio worth $0 as of Q3 2021.
Berman Capital Advisors bought 2 Kyntra Bio shares in Q3 2021, an estimated $709.
Kyntra Bio made up ﹤0.01% of Berman Capital Advisors's portfolio in Q3 2021, its #2117 holding.
Berman Capital Advisors first reported a position in Kyntra Bio in Q4 2018 and has held it in 8 quarters since.
Berman Capital Advisors's Kyntra Bio position peaked at $6K in Q1 2019.
164 funds tracked by Wall St. Rank held Kyntra Bio as of Q3 2021.

Based on Berman Capital Advisors's 13F filing for Q3 2021, filed 7 Oct 2021.